EU CHMP Recommends Approval of AstraZeneca’s Imfinzi for Bladder Cancer Treatment

PUBLISHED: 27 May 2025 @ 18:18 | Comments (0) | More info about Fiona Craig

AstraZeneca (LSE:AZN) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending Imfinzi for approval as the first perioperative immunotherapy for muscle-invasive bladder cancer. This endorsement follows results from the Phase III NIAGARA trial, which demonstrated a marked decrease in disease recurrence and mortality risk compared to standard neoadjuvant chemotherapy alone.

If approved, Imfinzi could establish a new treatment standard across Europe for patients with resectable muscle-invasive bladder cancer, potentially improving outcomes and offering a significant advancement in care.

Company Outlook

AstraZeneca remains a dominant force in the biopharmaceutical sector, particularly in oncology and immuno-oncology. The company’s strong financial health and recent strategic initiatives underpin a favorable long-term outlook. Nevertheless, near-term challenges including technical stock weaknesses and valuation pressures suggest cautious optimism among investors.

About AstraZeneca

AstraZeneca is a global biopharmaceutical leader focused on innovative treatments, with a special emphasis on oncology. Its portfolio includes Imfinzi, a monoclonal antibody immunotherapy approved for multiple cancer types. The company is committed to advancing cancer care through cutting-edge research and development of therapies that harness the immune system’s power.

Average Daily Trading Volume: 2,680,149
Technical Sentiment: Hold
Market Capitalization: £161.8 billion

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.